NERV Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.350

Open

6.030

VWAP

6.09

Vol

148.85K

Mkt Cap

258.35M

Low

5.940

Amount

906.01K

EV/EBITDA(TTM)

--

Total Shares

43.27M

EV

250.10M

EV/OCF(TTM)

--

P/S(TTM)

--

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Show More

Events Timeline

(ET)

2026-03-11

09:30:00

Minerva Files $200M Mixed Securities Shelf

2026-03-11

07:10:00

Minerva Neurosciences to Initiate Phase 3 Trial for Roluperidone

2025-12-23 (ET)

2025-12-23

18:30:00

Dow and S&P Futures Dip Marginally, Nasdaq Flat

2025-12-23

16:10:00

Minerva Files to Sell 94.6M Shares of Common Stock

2025-12-01 (ET)

2025-12-01

15:20:00

Jefferies Raises Minerva Price Target to $5, Maintains Hold Rating

2025-11-05 (ET)

2025-11-05

07:32:28

Minerva announces Q3 earnings per share of 36 cents, down from $2.97 a year ago.

2025-10-21 (ET)

2025-10-21

08:13:57

Minerva reveals funding of up to $200M to progress roluperidone development.

2025-05-13 (ET)

2025-05-13

07:34:16

Minerva reports Q1 EPS (50c) vs ($1.13) last year

News

seekingalpha

03-11seekingalpha

Minerva Neurosciences Files $200M Shelf Registration for Securities Offering

seekingalpha

03-11seekingalpha

Minerva Neurosciences Reports Q4 2025 Financial Results

Newsfilter

01-26Newsfilter

Minerva Neurosciences to Host KOL Event on Schizophrenia Treatment

TipRanks

2025-10-21TipRanks

Tuesday's Major Stock Market Highlights: Morning News Summary!

NASDAQ.COM

2025-10-21NASDAQ.COM

Minerva Neurosciences Soars 339% Following $200M Financing Deal

TipRanks

2025-10-21TipRanks

What’s Behind the 165% Surge in Minerva Neurosciences Stock (NERV) Today?

2 Analyst Rating

Wall Street analysts forecast NERV stock price to rise

0 Buy

2 Hold

0 Sell

Hold

Current: 0.000

Low

4.00

Averages

4.50

High

5.00

Current: 0.000

Low

4.00

Averages

4.50

High

5.00

H.C. Wainwright

Neutral

maintain

$4 -> $7

AI Analysis

2026-03-12

Reason

H.C. Wainwright

Price Target

$4 -> $7

AI Analysis

2026-03-12

maintain

Neutral

Reason

H.C. Wainwright raised the firm's price target on Minerva to $7 from $4 and keeps a Neutral rating on the shares. The firm cites the "promising positioning" of the new schizophrenia study for potential approval and additional funding to support its progress for the target boost.

H.C. Wainwright

Neutral

downgrade

$5 -> $4

2025-11-06

Reason

H.C. Wainwright

Price Target

$5 -> $4

2025-11-06

downgrade

Neutral

Reason

H.C. Wainwright lowered the firm's price target on Minerva to $4 from $5 and keeps a Neutral rating on the shares. The firm cites equity dilution for the target drop.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NERV

Unlock Now

Valuation Metrics

The current forward P/E ratio for Minerva Neurosciences Inc (NERV.O) is -7.00, compared to its 5-year average forward P/E of -1.83. For a more detailed relative valuation and DCF analysis to assess Minerva Neurosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.83

Current PE

-7.00

Overvalued PE

-0.29

Undervalued PE

-3.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

11.96

Current PS

0.00

Overvalued PS

38.96

Undervalued PS

-15.03

Financials

AI Analysis

Annual

Quarterly

Whales Holding NERV

Vivo Capital, LLC

Logos Global Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Minerva Neurosciences Inc (NERV) stock price today?

The current price of NERV is 5.97 USD — it has decreased -3.4

What is Minerva Neurosciences Inc (NERV)'s business?

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

What is the price predicton of NERV Stock?

Wall Street analysts forecast NERV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NERV is4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Minerva Neurosciences Inc (NERV)'s revenue for the last quarter?

Minerva Neurosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Minerva Neurosciences Inc (NERV)'s earnings per share (EPS) for the last quarter?

Minerva Neurosciences Inc. EPS for the last quarter amounts to -25.45 USD, increased 4444.64

How many employees does Minerva Neurosciences Inc (NERV). have?

Minerva Neurosciences Inc (NERV) has 7 emplpoyees as of March 31 2026.

What is Minerva Neurosciences Inc (NERV) market cap?

Today NERV has the market capitalization of 258.35M USD.